The relationship between pediatric combination vaccines and market effects

Banafsheh Behzad, Sheldon H. Jacobson, Janet A. Jokela, Edward C. Sewell

Research output: Contribution to journalArticlepeer-review

Abstract

We explored market factors that affect pediatric combination vaccine uptake in the US public-sector pediatric vaccine market. We specifically examined how Pediarix and Pentacel earned a place in the 2009-2012 lowest overall cost formulary. Direct competition between Pediarix and Pentacel is driven by the indirect presence of the Merck Haemophilus influenzae type b vaccine and the Recommended Childhood Immunization Schedule requirement for a hepatitis B birth dose. The resulting analysis suggests that Pentacel would never have earned a place in the lowest overall cost formulary for 2009-2012 federal contract prices for any cost of an injection unless the Merck H influenzae type b advantage was ignored and the hepatitis B birth dose administration cost was recognized by health care providers in designing the lowest overall cost formularies.

Original languageEnglish (US)
Pages (from-to)998-1004
Number of pages7
JournalAmerican journal of public health
Volume104
Issue number6
DOIs
StatePublished - Jun 2014

ASJC Scopus subject areas

  • Public Health, Environmental and Occupational Health

Fingerprint Dive into the research topics of 'The relationship between pediatric combination vaccines and market effects'. Together they form a unique fingerprint.

Cite this